Profiles of AdverseEvents, AventaMed, Ensysce Biosciences, Jounce Therapeutics, LensGen, Marvao Medical Devices, Pharmasum Therapeutics, and Rotation Medical.

Most individuals with Down syndrome who live long enough will develop Alzheimer’s disease, and Pharmasum Therapeutics AS hopes to develop an AD program by targeting a protein kinase that may underlie that association. The company intends to develop agents to treat AD in individuals with DS, a large and growing market, and potentially all other patients afflicted with Alzheimer’s.